Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ENROLLING BY INVITATION

NCT06401161

Study on the Effect of 3T Pu'er Tea in Regulating Glucose and Lipid Metabolism

Sponsor: Longgang District People's Hospital of Shenzhen

View on ClinicalTrials.gov

Summary

To study the effect of Pu'er tea in overweight / obese patients with blood glucose or abnormal lipid metabolism. Compared with the effect of two Pu'er tea with different tea fuscin content in improving glucose and lipid metabolism, to investigate the mechanisms of bile acid metabolism and intestinal flora regulation. In a prospective randomized controlled clinical study, 90 patients were divided into study group (3T Pu'er tea group, 45 patients) and control group ( traditional Pu'er tea group,45 patients). Before and after the treatment(0day, 12 weeks, 52 weeks) patients' markers of glucose and lipid metabolism were examined and compared.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2022-11-01

Completion Date

2025-12-31

Last Updated

2024-05-06

Healthy Volunteers

Conditions

Overweight Obesity

Interventions

OTHER

3T Pu'er tea

Two types of Pu-erh tea with different levels of theabrownin content.

Inclusion Criteria: The A、B should be simultaneously met, or combined with the C、D、E. 1. 18-65 years, priority for patients over 30 years; 2. Overweight / obese patients: BMI ≥24 kg/m2. 3. Or combined with nonalcoholic fatty liver disease: determined by the hospital MRI nuclear magnetic quantification; 4. Or combined with dyslipidemia: blood total cholesterol TC≥6.4mmol/L or blood total triglyceride TG≥2.0mmol/L or blood low-density lipoprotein LDL-C≥3.1mmol/L; 5. Or with abnormal blood glucose: * Impaired fasting glucose, IFG: fasting blood glucose was 6.1\~\<7.0mmol/L,and 2 hours after 75g oral blood glucose tolerance test(OGTT) \<7.8mmol / L. * Impaired glucose tolerance, IGT: the fasting blood glucose was \<6.1mmol/L and 2 hours after 75gOGTT was 7.8\~ \<11.1 mmol / L; * IFG with IGT: patients with both IFG and IGT; * Patients with type 2 diabetes: random blood glucose 11.1mmol/L or fasting glucose of 7.0 mmol/L or 2 hours after OGTT. Exclusion Criteria: 1. Type 2 diabetes and insulin injections or oral hypoglycemic drugs and other special types of diabetes. 2. For women during pregnancy or lactation or with allergies; 3. Patients treated with any hypoglycemic drugs and insulin injections; regular or planned patients taking drugs that may affect glucose and lipid metabolism (as judged by clinicians, such as diet pills, lipid-lowering drugs) and liver protection drugs (as judged by clinicians); 4. Patients with severe cardiovascular diseases, cerebrovascular diseases, liver, kidney, and hematopoietic diseases; 5. Combined with other infectious diseases, such as hepatitis A, hepatitis B, hepatitis C, and acquired immunodeficiency syndrome; 6. Take probiotics, prebiotics, antioxidants and fish oil nutrient supplements within 3 months; 7. Current smokers and regular drinking (excluding social drinkers only); 8. Yogurt intake within 1 week before the first visit and antibiotics within 3 months; 9. Drink strong tea regularly; 10. Participate in other clinical trials within 3 months; 11. Unable not cooperate with the investigator for other reasons. 12. Unfit for the researcherr.

Locations (1)

Longgang District People's Hospital of Shenzhen

Shenzhen, Guangdong, China